Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.3K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.3K
Antibody Structure01:10

Antibody Structure

65.4K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
65.4K
Antibody Actions01:26

Antibody Actions

2.4K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
2.4K
Antibody Structure and Classes01:25

Antibody Structure and Classes

8.4K
Antibodies, also known as immunoglobulins, are produced by B cells in response to foreign substances, such as bacteria and viruses. These proteins are critical for recognizing and neutralizing these substances, protecting the body from potential harm.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
8.4K
Sustainable Development01:43

Sustainable Development

14.8K
As the human population continues to grow and use resources, we must be mindful of our planet’s natural limits. Sustainable development provides a pathway to maintain and improve human life now while also ensuring that future generations will have the resources that they need. The long-term success of sustainability efforts rests on understanding the interplay between human actions and ecological systems.
14.8K
Development of the Lymphatic System01:15

Development of the Lymphatic System

2.0K
The development of lymphatic tissues and vessels in embryonic life begins around the fifth week. These structures originate from the mesoderm layer, with lymph sacs emerging from developing veins.
The first lymph sacs to form are the paired jugular lymph sacs located at the junction of the internal jugular and subclavian veins. From these sacs, lymphatic capillary plexuses extend to the thorax, upper limbs, neck, and head, eventually forming lymphatic vessels. Each jugular lymph sac maintains a...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Household Transmission of Enterovirus D68, Washington and Oregon, United States, 2022-2024.

Emerging infectious diseases·2026
Same author

Exclusion by design: enrollment criteria limit older adult participation in SARS-CoV-2 vaccine clinical trials.

Journal of clinical epidemiology·2026
Same author

Recent COVID-19 Vaccination and Risk of SARS-CoV-2 Transmission.

JAMA network open·2026
Same author

COVID-19 and Influenza Vaccine Acceptance and Hesitancy Among Caregivers of Children With Cancer.

Journal of pediatric hematology/oncology·2026
Same author

Human Infection with Highly Pathogenic Avian Influenza A(H5N5) Virus.

The New England journal of medicine·2026
Same author

Influenza household transmission and genomic diversity in the United States: A prospective cohort study, 2022-2024.

The Journal of infection·2026
Same journal

Phase 2/3, Open-label, Randomized, Active-controlled Clinical Trial Evaluating the Safety and Efficacy of Imipenem/Cilastatin/Relebactam in Pediatric Patients From Birth to Less Than 18 Years With Gram-negative Bacterial Infections.

The Pediatric infectious disease journal·2026
Same journal

Determinants of Severity in Pediatric Viral Lower Respiratory Tract Diseases From Emergency Department Presentation to Hospital Course.

The Pediatric infectious disease journal·2026
Same journal

Oropharyngeal Colonization by Kingella kingae and Septic Arthritis in Children 6-48 Months of Age: A Portuguese Multicenter Case-control Study.

The Pediatric infectious disease journal·2026
Same journal

Trends in Late-onset Sepsis in Very Low Birth Weight Preterm Infants in the Brazilian Network on Neonatal Research: A 10-year Cohort Study.

The Pediatric infectious disease journal·2026
Same journal

Severe Mycoplasma-induced Rash and Mucositis Mimicking Stevens-Johnson Syndrome Treated With Steroid Pulse Therapy: A Case Highlighting Diagnostic Challenges and Therapeutic Considerations.

The Pediatric infectious disease journal·2026
Same journal

Clindamycin Prophylaxis in Pediatric Punctate Outer Retinal Toxoplasmosis.

The Pediatric infectious disease journal·2026
See all related articles

Related Experiment Video

Updated: Jan 23, 2026

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

11.5K

RSV, Antibodies and the Developing World.

Alastair Murray1, Helen Y Chu2

  • 1From the School of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC.

The Pediatric Infectious Disease Journal
|June 18, 2019
PubMed
Summary
This summary is machine-generated.

Respiratory syncytial virus (RSV) causes severe infant illness globally, especially in developing nations. Prevention strategies like maternal vaccination and infant monoclonal antibodies show promise for protecting vulnerable newborns.

More Related Videos

Chemo-enzymatic Synthesis of N-glycans for Array Development and HIV Antibody Profiling
11:08

Chemo-enzymatic Synthesis of N-glycans for Array Development and HIV Antibody Profiling

Published on: February 5, 2018

9.1K
Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries
12:55

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Published on: January 17, 2015

19.2K

Related Experiment Videos

Last Updated: Jan 23, 2026

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

11.5K
Chemo-enzymatic Synthesis of N-glycans for Array Development and HIV Antibody Profiling
11:08

Chemo-enzymatic Synthesis of N-glycans for Array Development and HIV Antibody Profiling

Published on: February 5, 2018

9.1K
Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries
12:55

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Published on: January 17, 2015

19.2K

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Immunology

Background:

  • Respiratory syncytial virus (RSV) is a leading cause of severe respiratory illness in infants worldwide.
  • Infants in developing countries bear the highest mortality and morbidity burden from RSV.
  • Risk factors for severe RSV include household crowding, preterm birth, and low birth weight.

Purpose of the Study:

  • To summarize the global impact of respiratory syncytial virus on infant health.
  • To review risk factors contributing to severe RSV infection in infants.
  • To highlight emerging prevention strategies for respiratory syncytial virus.

Main Methods:

  • Literature review of RSV epidemiology and risk factors.
  • Analysis of maternal antibody transfer mechanisms (transplacental and breast milk).
  • Overview of current and developing preventative interventions.

Main Results:

  • RSV disproportionately affects infants in developing regions.
  • Maternal antibodies offer partial protection to newborns.
  • Vaccination during pregnancy and neonatal monoclonal antibody administration are promising interventions.

Conclusions:

  • Respiratory syncytial virus poses a significant global health threat to infants.
  • Understanding risk factors is crucial for targeted prevention.
  • Maternal immunization and passive antibody transfer are key future strategies against RSV.